1. Meaning of Sample Access Restrictions

Sample Access Restrictions refer to practices where a dominant or strategically important firm limits, delays, conditions, or completely refuses competitors’ access to product samples that are necessary for testing, regulatory approval, research, quality verification, or development of competing products.

The issue is particularly important in industries such as:

• Pharmaceuticals
• Chemicals
• Medical devices
• Biotechnology
• Food and agricultural products
• Consumer products requiring laboratory testing
• Technology products requiring interoperability or technical testing

A sample can be economically important even though the quantity involved is very small. For example, a generic pharmaceutical manufacturer may need a limited quantity of a branded medicine to conduct legally required bioequivalence testing. If the incumbent prevents access to the sample, the competitor may be unable to obtain regulatory approval and therefore cannot enter the market.

The FTC has specifically identified situations where restricted distribution systems were allegedly used to prevent generic manufacturers from obtaining branded-drug samples required for bioequivalence testing.

2. Why Sample Access Can Be a Competition Issue

Normally, competition law does not require every business to supply its competitors.

A company may generally choose:

• whom it sells to;
• how it distributes its products;
• what contractual conditions it uses; and
• whether to enter a commercial relationship.

However, the analysis changes when the following circumstances exist:

1. The supplier has substantial market power.
2. The sample is important or indispensable for competing.
3. Competitors cannot reasonably obtain an equivalent sample elsewhere.
4. Access is technically or legally necessary for market entry.
5. The restriction substantially reduces competitive pressure.
6. The supplier's stated justification appears inconsistent with its actual conduct.
7. The restriction forms part of a broader exclusionary strategy.

Thus, the central question is not simply:

“Did the company refuse to provide a sample?”

It is:

“Did the restriction use market power to prevent or substantially delay competition without a legitimate justification?”

3. Common Forms of Sample Access Restrictions

A. Complete refusal

The incumbent simply refuses to sell or provide samples to competing firms.

B. Restricted distribution

The company creates a distribution system through which competitors cannot purchase the product.

C. Quantity restrictions

The company allows sales but imposes quantities too small to permit meaningful testing.

D. Customer restrictions

Distributors are contractually prohibited from selling to competitors.

E. Approval requirements

Competitors must obtain approval from the incumbent before purchasing samples, with approval being withheld or delayed.

F. Excessive procedural requirements

The company demands unnecessary information or documentation that makes access practically impossible.

G. Differential treatment

Samples are supplied to:

• universities,
• research organizations,
• consultants,
• affiliated companies, or
• non-competing businesses,

but not to potential competitors.

This last situation can be particularly significant because it may undermine an argument that access is impossible for legitimate safety or regulatory reasons.

4. Legal Framework

A. Abuse of Dominance / Monopolization

In jurisdictions such as the European Union and India, sample restrictions may potentially be examined as exclusionary abuse of dominance where the undertaking has a dominant position.

Relevant concepts include:

• refusal to deal;
• denial of access to an essential input;
• discriminatory access;
• foreclosure of competitors;
• exclusionary agreements; and
• leveraging of market power.

Under EU competition law, Article 102 TFEU can apply where a dominant undertaking uses its position to restrict competition.

In India, Section 4 of the Competition Act, 2002 can become relevant where a dominant enterprise imposes conditions or engages in conduct that has an exclusionary effect.

5. Essential-Facility / Refusal-to-Deal Principles

Sample-access cases often overlap with the refusal-to-deal doctrine.

Courts generally approach compulsory access cautiously because forcing a company to deal with competitors can interfere with property rights, business freedom and incentives to invest.

The important question is therefore whether the circumstances are sufficiently exceptional to justify intervention.

Factors commonly considered include:

• indispensability;
• absence of realistic alternatives;
• elimination or substantial reduction of competition;
• feasibility of supplying;
• previous commercial dealing;
• legitimate business justification; and
• whether the refusal is part of an exclusionary strategy.

6. Important Case Laws

1. Aspen Skiing Co. v. Aspen Highlands Skiing Corp.

U.S. Supreme Court, 1985

This is one of the leading refusal-to-deal cases.

Aspen Skiing involved several ski areas that had previously participated in a joint ticket arrangement. The dominant operator later terminated the arrangement and refused to continue dealing with its rival.

The Supreme Court considered several factors, including:

• the parties' previous course of dealing;
• the profitability of the abandoned arrangement;
• the defendant's willingness to sacrifice short-term benefits; and
• the apparent exclusionary consequences.

Relevance to sample access

A sample-access restriction may become more concerning where the dominant company previously supplied samples but later stops doing so specifically when the requesting party becomes a competitive threat.

The case therefore provides an important framework for analysing whether termination of an existing relationship has an exclusionary purpose.

7. Verizon Communications Inc. v. Law Offices of Curtis V. Trinko, LLP

U.S. Supreme Court, 2004

The Supreme Court emphasized that antitrust law generally does not impose a broad obligation on companies to cooperate with competitors.

The Court was particularly concerned about forcing businesses to share facilities or services with rivals because compulsory sharing can create:

• administrative difficulties;
• uncertainty about appropriate terms;
• reduced investment incentives; and
• opportunities for regulatory disputes.

Relevance

Sample-access claims therefore cannot simply assume that a competitor automatically has a legal right to receive samples.

The claimant normally needs to demonstrate circumstances making the refusal sufficiently exceptional under applicable competition law.

8. Otter Tail Power Co. v. United States

U.S. Supreme Court, 1973

Otter Tail involved a vertically integrated electricity company that allegedly refused to provide transmission services to municipalities seeking to compete in electricity distribution.

The case is important because the Supreme Court recognized circumstances in which a monopolist's refusal to provide access to an important input could raise Section 2 concerns.

Relevance to sample restrictions

Where a sample is an indispensable input for regulatory approval or market entry, the logic of access-to-input cases can become relevant.

The stronger the evidence that:

• competitors cannot obtain the sample elsewhere, and
• access is necessary for entering the market,

the more significant the refusal may become from a competition perspective.

9. Actelion Pharmaceuticals Ltd. v. Apotex Inc.

U.S. District Court for the District of New Jersey, 2013 proceedings

This is one of the most directly relevant sample-access disputes.

Generic pharmaceutical companies sought samples of Actelion's Tracleer and Zavesca so they could conduct testing required for generic-drug approval.

Actelion's restricted distribution arrangements allegedly prevented generic manufacturers from obtaining the necessary samples.

The FTC submitted an amicus brief arguing that restricted distribution programs could improperly impede generic competition.

The case was significant because the samples were not merely commercially desirable—they were needed for the regulatory testing process.

Competition-law significance

It demonstrated how a seemingly legitimate distribution restriction can raise competition concerns where it effectively prevents potential rivals from completing regulatory requirements.

10. Mayor & City Council of Baltimore v. Actelion Pharmaceuticals Ltd.

995 F.3d 123 (4th Cir. 2021)

This case developed the Actelion sample-access dispute further.

Generic manufacturers repeatedly sought to purchase Tracleer samples. According to the allegations, Actelion refused those requests while also restricting its distributors from selling samples to generic manufacturers.

The Fourth Circuit reversed the district court's dismissal and allowed the plaintiffs' antitrust claims to proceed.

The case is especially important because the alleged restriction involved a product that competitors needed for bioequivalence testing.

Key lesson

A restricted distribution program does not automatically immunize a dominant company from antitrust scrutiny.

The actual structure and purpose of the restriction matter.

11. Natco Pharma Ltd. v. Gilead Sciences, Inc.

U.S. District Court for the District of Minnesota, 2015

Natco sought access to samples of a branded pharmaceutical product for bioequivalence testing.

The court considered the refusal-to-deal theory and the manufacturer's reliance on its restricted distribution program.

The case illustrates that not every refusal to provide pharmaceutical samples automatically establishes antitrust liability.

The court's treatment of the issue demonstrates the importance of examining:

• whether the plaintiff actually requested samples;
• whether the defendant refused them;
• the nature of the distribution restrictions; and
• whether the circumstances satisfy the demanding refusal-to-deal standard.

The case was later cited as instructive in litigation concerning other pharmaceutical sample-access disputes.

12. FTC v. Vyera Pharmaceuticals, LLC

U.S. District Court for the Southern District of New York

This is another major example.

The FTC and state authorities alleged that Vyera used restrictive distribution arrangements concerning Daraprim to prevent potential generic competitors from obtaining samples needed for FDA-required testing.

The alleged conduct included:

• restricting resale;
• monitoring distributor sales;
• limiting quantities;
• preventing suspected generic purchasers from obtaining the product; and
• restricting access to the active pharmaceutical ingredient.

The FTC's litigation ultimately produced significant judicial and injunctive consequences, and the Second Circuit affirmed the district court's ruling concerning Shkreli's conduct in 2024.

Competition significance

This case illustrates that sample restrictions can be examined as part of a broader exclusionary strategy, rather than as an isolated refusal.

13. Spring Pharmaceuticals, LLC v. Retrophin, Inc.

U.S. District Court for the Eastern District of Pennsylvania

Spring Pharmaceuticals alleged that Retrophin refused to provide samples of Thiola, which Spring needed to develop a generic product and proceed through the abbreviated regulatory approval process.

The case illustrates the practical importance of samples in pharmaceutical market entry.

Competition significance

The case demonstrates the connection between:

sample access → testing → regulatory approval → market entry → competitive pressure.

If the first step is blocked, the entire competitive process can potentially be delayed.

14. In re Revlimid & Thalomid Purchaser Antitrust Litigation

U.S. District Court for the District of New Jersey

This litigation involved allegations concerning Celgene's distribution systems for Revlimid and Thalomid.

Generic manufacturers allegedly could not obtain samples through normal wholesale channels because of the relevant REMS programs and therefore needed to obtain samples directly from Celgene.

The plaintiffs alleged that Celgene refused sample access to several generic manufacturers.

However, the court's later analysis also illustrates an important limitation: a refusal-to-deal claim may fail where the required elements are not adequately established.

The court distinguished Aspen Skiing, emphasizing the absence of allegations showing a prior voluntary and profitable course of dealing with the relevant competitors.

Lesson

Sample restrictions can be competition-sensitive, but economic importance alone does not automatically create antitrust liability.

15. Government Employees Health Association v. Actelion Pharmaceuticals Ltd.

This later litigation involved purchasers alleging that restrictions on Tracleer samples contributed to delayed generic competition.

The underlying allegations concerned the inability of generic manufacturers to obtain samples required for bioequivalence studies.

The case demonstrates that sample-access restrictions can potentially affect not only competing manufacturers but also:

• insurers,
• healthcare purchasers,
• consumers, and
• downstream markets.

16. Comparison of the Main Cases

17. When Sample Access Restrictions Become Particularly Problematic

A competition authority or court may pay greater attention where several factors occur together.

1. Market dominance

The supplier controls a substantial share of the relevant market.

2. No realistic alternative

Competitors cannot obtain equivalent samples from another source.

3. Regulatory necessity

The sample is required to satisfy regulatory testing.

4. Competitor-specific restriction

The company supplies samples to researchers or other customers but refuses competitors.

5. Sudden change in conduct

The company historically supplied the product but stops once competitive entry becomes imminent.

6. Contractual foreclosure

Distributors are prohibited from selling to potential competitors.

7. Excessive delay

The company technically permits access but imposes procedures that make timely testing impossible.

8. Broader exclusionary conduct

Sample restrictions occur together with:

• exclusive supply agreements;
• data restrictions;
• resale restrictions;
• loyalty arrangements;
• tying;
• discriminatory access; or
• other barriers to entry.

The Vyera matter is an example in which alleged sample restrictions appeared alongside other restrictions affecting generic entry.

18. Legitimate Business Justifications

Not every sample restriction is anti-competitive.

A company may have legitimate reasons to control access, including:

• safety concerns;
• regulatory requirements;
• product handling risks;
• confidentiality;
• intellectual-property protection;
• preventing misuse;
• preventing diversion;
• quality-control requirements;
• legitimate supply shortages; or
• restrictions imposed by law.

The important question is whether the justification is genuine, proportionate and consistently applied.

For example, if safety is the stated reason for refusing competitors but the company routinely supplies the same product to unrelated research organizations under comparable circumstances, that difference could become relevant evidence.

The FTC specifically highlighted allegations in the Actelion dispute that the company supplied products to non-competitor research organizations while restricting generic competitors.

19. Effects on Competition

Sample restrictions can produce several competitive effects.

A. Delayed market entry

Competitors cannot complete testing.

B. Reduced generic competition

Potential generic manufacturers may abandon development.

C. Higher prices

The incumbent faces less competitive pressure.

D. Reduced innovation

Potential entrants may have less incentive to develop competing products.

E. Increased barriers to entry

The restriction becomes an additional obstacle beyond patents or regulatory requirements.

F. Market foreclosure

Potential competitors are prevented from reaching customers even though they may otherwise be capable of competing.

20. Sample Access and Essential Facilities

The concept can be understood through a simple chain:

Dominant firm → controls necessary sample → competitor cannot obtain equivalent sample → testing cannot be completed → regulatory approval delayed → market entry delayed → competition reduced.

However, the mere fact that a sample is useful or important does not automatically make it an essential facility.

Courts generally require a strong factual showing before imposing compulsory access obligations.

21. Sample Access Restrictions Under Indian Competition Law

Under India's Competition Act, 2002, the issue would generally be analysed through the framework of abuse of dominance under Section 4 where the relevant enterprise is dominant.

Potentially relevant forms of conduct include:

• denial of market access;
• discriminatory conditions;
• exclusionary agreements;
• limiting production or technical development;
• practices resulting in foreclosure of competitors.

A sample restriction could therefore become relevant where it effectively prevents another enterprise from entering or competing in the relevant market.

The analysis would normally require establishing:

Relevant market → Dominance → Conduct → Exclusionary effect → Competitive harm → Absence or weakness of legitimate justification.

22. Important Distinction: Legitimate Access Control vs. Anticompetitive Foreclosure

23. Key Legal Test

A useful analytical framework is:

Step 1 — Define the relevant market

Determine the product and geographic market affected.

Step 2 — Establish market power

Determine whether the sample provider has substantial market power or dominance.

Step 3 — Identify the sample

Ask exactly what sample is being withheld.

Step 4 — Determine its competitive importance

Is it merely convenient, or is it necessary for:

• testing,
• certification,
• regulatory approval,
• interoperability, or
• product development?

Step 5 — Examine alternatives

Can competitors obtain an equivalent sample elsewhere?

Step 6 — Examine the refusal

Was access:

• denied,
• delayed,
• restricted,
• conditioned,
• priced excessively, or
• limited through distributors?

Step 7 — Examine discrimination

Does the firm provide samples to non-competitors but deny them to competitors?

Step 8 — Examine justification

Is there a legitimate safety, regulatory or commercial reason?

Step 9 — Examine competitive effects

Has the conduct:

• delayed entry,
• increased barriers,
• eliminated potential competition,
• reduced output, or
• protected the incumbent from competitive pressure?

Step 10 — Consider the overall strategy

The strongest cases may involve sample restrictions combined with other exclusionary practices.

24. Conclusion

Sample Access Restrictions become a competition-law concern when control over samples is used by a powerful incumbent to prevent or materially delay rivals from entering or competing in a market.

The most directly relevant pharmaceutical cases—particularly Actelion, Baltimore v. Actelion, Natco, Spring Pharmaceuticals, Vyera, and the Revlimid/Thalomid litigation—show why the issue is fact-specific.

The central distinction is between legitimate control over a product and using control over an otherwise necessary input to foreclose competition.

Importantly, courts do not treat every refusal to supply a competitor as unlawful. Trinko demonstrates the general caution against imposing a broad duty to deal, while Aspen Skiing and Otter Tail illustrate circumstances in which refusal to provide access can receive closer antitrust scrutiny.